TrianglePUBLICATIONS · 35763704
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2022 Sep 1
- First author
- Huober J
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Huober J
- type
- Author
- name
- Barrios CH
- type
- Author
- name
- Niikura N
- type
- Author
- name
- Jarząb M
- type
- Author
- name
- Chang YC
- type
- Author
- name
- Huggins-Puhalla SL
- type
- Author
- name
- Pedrini J
- type
- Author
- name
- Zhukova L
- type
- Author
- name
- Graupner V
- type
- Author
- name
- Eiger D
- type
- Author
- name
- Henschel V
- type
- Author
- name
- Gochitashvili N
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Huober J
- type
- Author
- name
- Barrios CH
- type
- Author
- name
- Niikura N
- type
- Author
- name
- Jarząb M
- type
- Author
- name
- Chang YC
- type
- Author
- name
- Huggins-Puhalla SL
- type
- Author
- name
- Pedrini J
- type
- Author
- name
- Zhukova L
- type
- Author
- name
- Graupner V
- type
- Author
- name
- Eiger D
- type
- Author
- name
- Henschel V
- type
- Author
- name
- Gochitashvili N
- type
- Author
- bibliography ids
- nci-bib-6c99f1c46dab2b671035b404
- book metadata
- content sha256
- 666471f8ad9af4011d09421f254acac65d882027b2b1a89782cc2fdb001149ed
- document type
- citation
- dois
- 10.1200/JCO.21.02772
- electronic publication date
- display
- 2022 Jun 28
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:35763704
- immutable id
- pubmed:35763704@666471f8ad9af4011d09421f254acac65d882027b2b1a89782cc2fdb001149ed
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 25
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 2946-2956
- volume
- 40
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 35763704
- provenance
- batch id
- 9d150d55960e0c12aada
- provider
- NCBI PubMed ESummary
- record sha256
- 40f5d99501df3e0a39d409c3664000bd931950dd2e04c3e581ed251b6210527b
- response sha256
- 2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
- retrieved at
- 2026-09-09T23:48:09.820498+00:00
- publication date
- display
- 2022 Sep 1
- precision
- day
- year
- 2022
- publication types
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Preserved source evidence · Not medical advice